360 High-Risk Vulnerability Immunization Tool V2.0 vs Rapid7 Nexpose: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

Rapid7 Nexpose: On-premise vulnerability scanner with asset discovery and risk prioritization. built by Rapid7. Core capabilities include Real Risk Score with 1-1000 scale incorporating vulnerability age and exploit data, Adaptive Security for automatic detection and assessment of new devices, Policy assessment and benchmarking against CIS and NIST standards..

Both serve the Vulnerability Assessment market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Rapid7 Nexpose differentiates with Real Risk Score with 1-1000 scale incorporating vulnerability age and exploit data, Adaptive Security for automatic detection and assessment of new devices, Policy assessment and benchmarking against CIS and NIST standards.

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Rapid7 Nexpose is developed by Rapid7. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

360 High-Risk Vulnerability Immunization Tool V2.0 and Rapid7 Nexpose serve similar Vulnerability Assessment use cases: both are Vulnerability Assessment tools. Review the feature comparison above to determine which fits your requirements.